17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations

      research-article
      1 , 2 , , 3 , 4 , 5 , 6 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 6 , 7 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 10 , 11 , 31 , 32 , 33 , 34 , 26 , 35 , 36 , 18 , 19
      United European Gastroenterology Journal
      John Wiley and Sons Inc.
      budesonide, diarrhoea, inflammatory bowel disease, microscopic colitis

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Microscopic colitis is a chronic inflammatory bowel disease characterised by normal or almost normal endoscopic appearance of the colon, chronic watery, nonbloody diarrhoea and distinct histological abnormalities, which identify three histological subtypes, the collagenous colitis, the lymphocytic colitis and the incomplete microscopic colitis. With ongoing uncertainties and new developments in the clinical management of microscopic colitis, there is a need for evidence‐based guidelines to improve the medical care of patients suffering from this disorder.

          Methods

          Guidelines were developed by members from the European Microscopic Colitis Group and United European Gastroenterology in accordance with the Appraisal of Guidelines for Research and Evaluation II instrument. Following a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the certainty of the evidence. Statements and recommendations were developed by working groups consisting of gastroenterologists, pathologists and basic scientists, and voted upon using the Delphi method.

          Results

          These guidelines provide information on epidemiology and risk factors of microscopic colitis, as well as evidence‐based statements and recommendations on diagnostic criteria and treatment options, including oral budesonide, bile acid binders, immunomodulators and biologics. Recommendations on the clinical management of microscopic colitis are provided based on evidence, expert opinion and best clinical practice.

          Conclusion

          These guidelines may support clinicians worldwide to improve the clinical management of patients with microscopic colitis.

          Related collections

          Most cited references352

          • Record: found
          • Abstract: found
          • Article: not found

          European consensus on the histopathology of inflammatory bowel disease.

          The histologic examination of endoscopic biopsies or resection specimens remains a key step in the work-up of affected inflammatory bowel disease (IBD) patients and can be used for diagnosis and differential diagnosis, particularly in the differentiation of UC from CD and other non-IBD related colitides. The introduction of new treatment strategies in inflammatory bowel disease (IBD) interfering with the patients' immune system may result in mucosal healing, making the pathologists aware of the impact of treatment upon diagnostic features. The European Crohn's and Colitis Organisation (ECCO) and the European Society of Pathology (ESP) jointly elaborated a consensus to establish standards for histopathology diagnosis in IBD. The consensus endeavors to address: (i) procedures required for a proper diagnosis, (ii) features which can be used for the analysis of endoscopic biopsies, (iii) features which can be used for the analysis of surgical samples, (iv) criteria for diagnosis and differential diagnosis, and (v) special situations including those inherent to therapy. Questions that were addressed include: how many features should be present for a firm diagnosis? What is the role of histology in patient management, including search for dysplasia? Which features if any, can be used for assessment of disease activity? The statements and general recommendations of this consensus are based on the highest level of evidence available, but significant gaps remain in certain areas. Copyright © 2013 European Crohn's and Colitis Organisation. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group.

              Quality of life (QOL), a subjective index of health perception and function, embraces physical, social, and emotional performance but has not had a prominent role in clinical trials of inflammatory bowel disease (IBD). To test the robustness of the Inflammatory Bowel Disease Questionnaire (IBDQ), a disease-specific QOL index, this study assessed its validity, reliability, and responsiveness during a multicenter trial. Three hundred five patients with stable Crohn's disease received cyclosporin or placebo for 18 months. IBDQ and dimensional scores (bowel, social, systemic, and emotional) were correlated with disease activity (Crohn's disease activity index [CDAI] and Harvey-Bradshaw index). Concordance of IBDQ scores was tested in 280 stable subjects. Linear regression evaluated change in IBDQ scores over time. IBDQ scores correlated highly with CDAI (r = -0.67; P < 0.0001). The reliability coefficient for IBDQ score was 0.70 vs. 0.66 for CDAI and 0.55 for Harvey-Bradshaw index. Regression line slopes of IBDQ scores were significantly different in patients who deteriorated from those who remained stable ([b] < 0.15; P < 0.0001). QOL scores were lower in patients who required surgery. The IBDQ is a valid reliable assessment tool that reflects important changes in the health status of patients with IBD. The IBDQ is a robust measure of therapeutic efficacy and should be used in future clinical trials in IBD.
                Bookmark

                Author and article information

                Contributors
                miehlke@faz-eppendorf.de
                Journal
                United European Gastroenterol J
                United European Gastroenterol J
                10.1002/(ISSN)2050-6414
                UEG2
                United European Gastroenterology Journal
                John Wiley and Sons Inc. (Hoboken )
                2050-6406
                2050-6414
                22 February 2021
                February 2021
                : 9
                : 1 ( doiID: 10.1002/ueg2.v9.1 )
                : 13-37
                Affiliations
                [ 1 ] Center for Digestive Diseases Internal Medicine Center Eppendorf Hamburg Germany
                [ 2 ] Center for Esophageal Disorders University Hospital Eppendorf Hamburg Germany
                [ 3 ] Neuro‐Immuno‐Gastroenterology Group Digestive Physiology and Pathophysiology Unit Vall d'Hebron Research Institute (VHIR) Barcelona Spain
                [ 4 ] Digestive System Department Vall d'Hebron University Hospital Barcelona Spain
                [ 5 ] Faculty of Medicine Autonomous University of Barcelona Bellaterra Spain
                [ 6 ] Centro de Investigación Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Barcelona Spain
                [ 7 ] Department of Gastroenterology Hospital Universitari Mutua de Terrassa University of Barcelona Barcelona Spain
                [ 8 ] Department of Pathophysiology and Organ Transplantation University of Milan and Gastroenterology and Endoscopy Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
                [ 9 ] Department of Pathology Copenhagen University Hospital Rigshospitalet Denmark
                [ 10 ] Department of Gastroenterology Zealand University Hospital Koege Denmark
                [ 11 ] Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
                [ 12 ] Department of Medicine Örebro University Hospital Örebro University Örebro Sweden
                [ 13 ] Diagnostik Center Hospitalenhed Midt Regionshospitalet Silkeborg Silkeborg Denmark
                [ 14 ] Department of Gastroenterology and Hepatology Vrije Universiteit Amsterdam Amsterdam the Netherlands
                [ 15 ] School of Biological Sciences Monash University Clayton Australia
                [ 16 ] Department of Pathology Zealand University Hospital Roskilde Denmark
                [ 17 ] Hepatogastroenterology Unit Centre Hospitalier de Marne‐la‐Vallee Jossigny France
                [ 18 ] Department of Gastroenterology and Hepatology in Linköping Linköping University Linköping Sweden
                [ 19 ] Department of Health Medicine, and Caring Sciences Linköping University Linköping Sweden
                [ 20 ] School of Medical Sciences Örebro University Örebro Sweden
                [ 21 ] The Royal Infirmary of Edinburgh Endoscopy Unit Edinburgh UK
                [ 22 ] Department of Gastroenterology and Institute for Digestive Research Lithuanian University of Health Sciences Kaunas Lithuania
                [ 23 ] Department of Pathology Hospital Universitari Vall d'Hebron CIBERONC Barcelona Spain
                [ 24 ] Department of Life, Health and Environmental Sciences University of L'Aquila L'Aquila Italy
                [ 25 ] Department of Gastroenterology Hospital General de Tomelloso Tomelloso Spain
                [ 26 ] Department of Gastroenterology Medical University of Sofia University Hospital Tsaritsa Yoanna—ISUL Sofia Bulgaria
                [ 27 ] Department of Gastroenterology CRH Clinic Siloah Hannover Germany
                [ 28 ] Department of Pharmacology Hospital de Sao Joao Porto Portugal
                [ 29 ] Department of Gastroenterology Pomeranian Medical University Szczecin Poland
                [ 30 ] Department of Internal Medicine Semmelweis University Budapest Hungary
                [ 31 ] Department of Clinical and Molecular Medicine NTNU: Norwegian University of Science and Technology Trondheim Norway
                [ 32 ] Department of Gastroenterology and Hepatology St Olav's University Hospital Trondheim Norway
                [ 33 ] 2nd Department of Medicine Semmelweis University Budapest Hungary
                [ 34 ] Department of Medicine Mayo Clinic Rochester Minnesota USA
                [ 35 ] Department of Human Nutrition and Metabolomics Pomeranian Medical University Szczecin Poland
                [ 36 ] Department of Internal Medicine Maastricht University Medical Center Maastricht The Netherlands
                Author notes
                [*] [* ] Correspondence

                Stephan Miehlke, Center for Digestive Diseases, Internal Medicine Center Eppendorf, Center for Esophageal Disorders, University Hospital Eppendorf, Eppendorfer Landstraûe 42, 20249 Hamburg, Germany.

                Email: miehlke@ 123456faz-eppendorf.de

                Author information
                https://orcid.org/0000-0002-1059-635X
                https://orcid.org/0000-0003-1183-1072
                https://orcid.org/0000-0001-8883-1121
                https://orcid.org/0000-0002-2649-5967
                https://orcid.org/0000-0003-1863-5971
                Article
                UEG212035
                10.1177/2050640620951905
                8259259
                33619914
                473c6e26-f215-4bee-8203-2d1246b68589
                © 2020 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 28 May 2020
                : 27 July 2020
                Page count
                Figures: 1, Tables: 1, Pages: 25, Words: 19867
                Categories
                Review Article
                Luminal
                Custom metadata
                2.0
                February 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.4 mode:remove_FC converted:06.07.2021

                budesonide,diarrhoea,inflammatory bowel disease,microscopic colitis

                Comments

                Comment on this article